OrbiMed Genesis GP LLC, Director, 10% Owner at Terns Pharmaceuticals, Inc. (TERN), sold 56,164 shares at $10.00 ($562K) on 2024-07-16, disclosed to the SEC on 2024-07-17.
Open-market sale of $562k TERN by Director, 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.00 | 5,401 | $54K | 9.6% |
| 2 | $10.00 | 6,142 | $61K | 10.9% |
| 3 | $10.00 | 39,433 | $394K | 70.2% |
| 4 | $10.00 | 556 | $6K | 1.0% |
| 5 | $10.00 | 623 | $6K | 1.1% |
| 6 | $10.00 | 4,009 |
| $40K |
| 7.1% |
| Total | $10.00 avg | 56,164 | $562K | 100% |
| Filing → |
| MBX | BUY | 2025-02-19 | $2.7M | — | Filing → |
| KROS | SELL | 2024-08-15 | $11.0M | — | Filing → |
| IRON | BUY | 2024-06-20 | $3.0M | — | Filing → |